This Article Full Text Full Text (PDF) All Versions of this Article: 36/6/1189    most recent 01.STR.0000166054.55993.e5v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blanco, M. Articles by Castillo, J. Search for Related Content PubMed PubMed Citation Articles by Blanco, M. Articles by Castillo, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Stroke Related Collections Cerebrovascular disease/stroke Mechanism of atherosclerosis/growth factors Risk Factors Ischemic biology - basic studies

(Stroke. 2005;36:1189.)
© 2005 American Heart Association, Inc.

Original Contributions

Increased Plasma Levels of 15-Deoxy Prostaglandin J₂ Are Associated With Good Outcome in Acute Atherothrombotic Ischemic Stroke

Miguel Blanco, MD, PhD; María Ángeles Moro, PhD; Antonio Dávalos, MD, PhD; Rogelio Leira, MD, PhD; Mar Castellanos, MD, PhD; Joaquín Serena, MD, PhD; José Vivancos, MD, PhD; Manuel Rodríguez-Yáñez, MD; Ignacio Lizasoain, MD, PhD José Castillo, MD, PhD

From the Department of Neurology (M.B., R.L., M.R.-Y., J.C.), Hospital Clínico Universitario, University of Santiago de Compostela, Santiago de Compostela; the Department of Pharmacology (M.A.M., I.L.), School of Medicine, University Complutense de Madrid, Madrid; the Department of Neurosciences (A.D.), Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona; the Department of Neurology (M.C., J.S.), Hospital Universitario Doctor Josep Trueta, Girona; and the Department of Neurology (J.V.), Hospital Universitario La Princesa, Madrid, Spain.

Correspondence to José Castillo, Servicio de Neurología- Sección Neurovascular y Unidad de Ictus, Hospital Clínico Universitario, Travesa da Choupana, s/n, 15706 Santiago de Compostela, Spain. E-mail mecasti{at}usc.es

Background and Purpose— The 15-deoxy prostaglandin J₂ (15-dPGJ₂) is an anti-inflammatory prostaglandin that has been proposed to be the endogenous ligand of peroxisome proliferator-activated receptor- (PPAR), a nuclear receptor that can exert potent anti-inflammatory actions by repressing inflammatory genes when activated. It has been suggested that 15-dPGJ₂ could be beneficial in neurological disorders in which inflammation contributes to cell death such as stroke.

Methods— We investigated the relationship between plasma levels of 15-dPGJ₂ and early neurological deterioration (END), infarct volume, and neurologic outcome in 552 patients with an acute stroke admitted within 24 hours after symptoms onset.

Results— Median [quartiles] plasma 15-dPGJ₂ levels on admission were significantly higher in patients than in controls (60.5 [11.2 to 109.4] versus 5.0 [3.8 to 7.2] pg/mL; P<0.0001). Levels of this prostaglandin were also significantly higher in patients with vascular risk factors (history of hypertension or diabetes) and with atherothrombotic infarcts (113.9 [81.6 to 139.7] pg/mL), than in those with lacunar (58.7 [32.7 to 86.2] pg/mL), cardioembolic (12.1 [6.5 to 39.2] pg/mL), or undetermined origin infarcts (11.4 [5.6 to 24.3] pg/mL) (P<0.0001). In the subgroup of patients with atherothrombotic infarcts, the adjusted odds ratio of END and poor outcome for 1 pg/mL increase in 15-dPGJ₂ were 0.95 (95% CI, 0.94 to 0.97) and 0.97 (95% CI, 0.96 to 0.98), respectively. In a generalized linear model, by 1 U increase in 15-dPGJ₂, there was a reduction of 0.47 mL (95% CI, 0.32 to 0.63) in the mean estimated infarct volume.

Conclusions— Increased plasma 15-dPGJ₂ concentration is associated with good early and late neurological outcome and smaller infarct volume. These findings suggest a neuroprotective effect of 15-dPGJ₂ in atherothrombotic ischemic stroke.

Key Words: atherosclerosis • diabetes mellitus • hypertension • inflammation • stroke

This article has been cited by other articles:

				M. Collino, N. S.A. Patel, and C. Thiemermann Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 179 - 197. [Abstract] [PDF]

				T. E. Taylor-Clark, B. J. Undem, D. W. MacGlashan Jr., S. Ghatta, M. J. Carr, and M. A. McAlexander Prostaglandin-Induced Activation of Nociceptive Neurons via Direct Interaction with Transient Receptor Potential A1 (TRPA1) Mol. Pharmacol., February 1, 2008; 73(2): 274 - 281. [Abstract] [Full Text] [PDF]

				J. F. Arenillas, M. A. Moro, and A. Davalos The Metabolic Syndrome and Stroke: Potential Treatment Approaches Stroke, July 1, 2007; 38(7): 2196 - 2203. [Full Text] [PDF]

				K. T. Chambers, S. M. Weber, and J. A. Corbett PGJ2-stimulated beta-cell apoptosis is associated with prolonged UPR activation Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1052 - E1061. [Abstract] [Full Text] [PDF]

				S.-W. Park, J.-H. Yi, G. Miranpuri, I. Satriotomo, K. Bowen, D. K. Resnick, and R. Vemuganti Thiazolidinedione Class of Peroxisome Proliferator-Activated Receptor {gamma} Agonists Prevents Neuronal Damage, Motor Dysfunction, Myelin Loss, Neuropathic Pain, and Inflammation after Spinal Cord Injury in Adult Rats J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1002 - 1012. [Abstract] [Full Text] [PDF]